Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeVVOSVivos Therapeutics$3.78-2.3%$4.87$1.98▼$7.95$28.37M7.02373,227 shs62,498 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceVVOSVivos Therapeutics+1.04%-8.51%-12.05%+74.32%+30.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeVVOSVivos Therapeutics$3.78-2.3%$4.87$1.98▼$7.95$28.37M7.02373,227 shs62,498 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceVVOSVivos Therapeutics+1.04%-8.51%-12.05%+74.32%+30.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceVVOSVivos Therapeutics 2.50Moderate Buy$4.9230.07% UpsideCurrent Analyst Ratings BreakdownLatest VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.20 ➝ $6.50(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookVVOSVivos Therapeutics$14.39M1.97N/AN/A$1.35 per share2.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateVVOSVivos Therapeutics-$11.14M-$1.68N/AN/AN/A-99.49%-232.76%-84.30%11/13/2025 (Estimated)Latest VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025VVOSVivos Therapeutics-$0.39-$0.55-$0.16-$0.55$3.37 million$3.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioVVOSVivos Therapeutics1.691.051.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipVVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipVVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableVVOSVivos Therapeutics1607.51 million7.28 millionOptionableVVOS HeadlinesRecent News About These CompaniesVivos Therapeutics’ Earnings Call: Strategic Transition and GrowthAugust 31, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call TranscriptAugust 22, 2025 | seekingalpha.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2025 Earnings Call TranscriptAugust 21, 2025 | msn.comVivos Reports 7% Sales DropAugust 21, 2025 | aol.comAVivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 20, 2025 | finanznachrichten.deVivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 19, 2025 | globenewswire.comVivos Therapeutics, Inc. Announces Upcoming Release of Second Quarter 2025 Financial Results and Conference CallAugust 19, 2025 | quiverquant.comQVivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference CallAugust 19, 2025 | globenewswire.comVivos Therapeutics Delays Q2 2025 10-Q FilingAugust 14, 2025 | msn.comVivos Therapeutics Adds to Management Team to Support Expansion and GrowthJuly 30, 2025 | finance.yahoo.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceJuly 1, 2025 | taiwannews.com.twTVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comVivos Therapeutics Shares Skyrocket After Medicare Greenlights VidaSleep Oral DeviceJuly 1, 2025 | msn.comVivos Therapeutics Secures CMS Approval for VidaSleep™ Oral Appliance, Expanding Access to Sleep Apnea TreatmentJuly 1, 2025 | quiverquant.comQNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | finance.yahoo.comNew Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in ChildrenJune 26, 2025 | globenewswire.comVivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finanznachrichten.deVivos Therapeutics Completes Acquisition of The Sleep Center of NevadaJune 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVVOS Company DescriptionsVivos Therapeutics NASDAQ:VVOS$3.78 -0.09 (-2.33%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
